-

Diagnostic Collaboration and Licensing Agreements Analysis 2025 with Directory of 1449 Deals Signed Since 2015 - Unprecedented Access to Deal Structures with Links to Contract Documents - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Diagnostic Collaboration and Licensing Deals 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The report provides a detailed understanding and analysis of how and why companies enter diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report contains a comprehensive listing of 1449 diagnostic deals announced since 2020 including financial terms where available including links to online deal records of actual diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in diagnostic dealmaking since 2020.

Chapter 3 provides an overview of the leading diagnostic deals since 2020. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in diagnostic dealmaking with a brief summary followed by a comprehensive listing of diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of diagnostic deals signed and announced since Jan 2020, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of diagnostic partnering deals signed and announced since Jan 2020. The chapter is organized by specific diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in diagnostic deal making since 2020.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2020
  • Browse diagnostic collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, deal type and therapy area
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in diagnostic dealmaking

2.1. Introduction

2.2. Diagnostic deals over the years

2.3. Most active diagnostic dealmakers

2.4. Diagnostic deals by deal type

2.5. Diagnostic deals by therapy area

2.6. Diagnostic deals by industry sector

2.7. Deal terms for diagnostic deals

2.7.1 Diagnostic deals headline values

2.7.2 Diagnostic deal upfront payments

2.7.3 Diagnostic deal milestone payments

2.7.4 Diagnostic royalty rates

Chapter 3 - Leading diagnostic deals

3.1. Introduction

3.2. Top diagnostic deals by value

Chapter 4 - Most active diagnostic dealmakers

4.1. Introduction

4.2. Most active diagnostic dealmakers

4.3. Most active diagnostic deals company profiles

Chapter 5 - Diagnostic contracts dealmaking directory

5.1. Introduction

5.2. Diagnostic contracts dealmaking directory

Chapter 6 - Diagnostic dealmaking by technology type

For more information about this report visit https://www.researchandmarkets.com/r/j5wgt9

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Pharmaceutical Regulatory Affairs in Asia Training Course: Important Aspects of Gaining and Maintaining a Successful Marketing Authorisation (Mar 24th - Mar 26th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Regulatory Affairs in Asia Training Course (Mar 24th - Mar 26th, 2026)" training has been added to ResearchAndMarkets.com's offering. The pharmaceutical market in Asia is growing at a rapid pace and presents both opportunities and challenges to those wishing to work in the region. Rather than a single market, Asia is a collection of different markets, each with their own regulatory processes, although harmonisation exists within the ASEAN countries....

European Union Veterinary Pharmacovigilance Introductory Training Course: Practical Guidance and Basic Training for All Those Working in Drug Safety (Mar 9th - Mar 10th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Introduction to Veterinary Pharmacovigilance Training Course (Mar 9th - Mar 10th, 2026)" training has been added to ResearchAndMarkets.com's offering. This two-day event has been designed to provide an essential overview of veterinary pharmacovigilance and will offer practical guidance and basic training for all those working in drug safety in the EU. Our experienced trainer will clarify roles and responsibilities, explain commonly used terminology and take partici...

Pharma and Medical Device Clinical Quality Management Systems Training Course: EMA Guidance on Computerised Systems and ICH GCP R3 Data Governance (Mar 23rd - Mar 24th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Clinical Quality Management Systems Training Course (Mar 23rd - Mar 24th, 2026)" training has been added to ResearchAndMarkets.com's offering. This course will provide essential information and guidance to help you achieve regulatory compliance in this evolving area of clinical quality, including EMA guidance on computerised systems and ICH GCP R3 data governance. With increasing clinical quality standards required by inspectors, there is currently no harmonised re...
Back to Newsroom